Cargando…

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective th...

Descripción completa

Detalles Bibliográficos
Autores principales: Makita, Shinichi, Imaizumi, Katsuaki, Kurosawa, Saiko, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385623/
https://www.ncbi.nlm.nih.gov/pubmed/30815024
http://dx.doi.org/10.7573/dic.212567
_version_ 1783397241438863360
author Makita, Shinichi
Imaizumi, Katsuaki
Kurosawa, Saiko
Tobinai, Kensei
author_facet Makita, Shinichi
Imaizumi, Katsuaki
Kurosawa, Saiko
Tobinai, Kensei
author_sort Makita, Shinichi
collection PubMed
description B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Nonetheless, there remain several controversial issues and problems awaiting solutions, including optimal management of toxicities, overcoming relapsed/refractory disease after CAR T-cell therapy, and improving CAR-T manufacturing platform. Definite unmet medical needs among patients with chemorefractory B-cell NHL still exist. CAR T-cell therapy might be a game changer that can defeat chemorefractory B-cell NHL, and further clinical development is warranted. In this review, we summarize the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy, focusing on B-cell NHL.
format Online
Article
Text
id pubmed-6385623
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-63856232019-02-27 Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges Makita, Shinichi Imaizumi, Katsuaki Kurosawa, Saiko Tobinai, Kensei Drugs Context Review B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Nonetheless, there remain several controversial issues and problems awaiting solutions, including optimal management of toxicities, overcoming relapsed/refractory disease after CAR T-cell therapy, and improving CAR-T manufacturing platform. Definite unmet medical needs among patients with chemorefractory B-cell NHL still exist. CAR T-cell therapy might be a game changer that can defeat chemorefractory B-cell NHL, and further clinical development is warranted. In this review, we summarize the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy, focusing on B-cell NHL. BioExcel Publishing Ltd 2019-02-13 /pmc/articles/PMC6385623/ /pubmed/30815024 http://dx.doi.org/10.7573/dic.212567 Text en Copyright © 2019 Makita S, Imaizumi K, Kurosawa S, Tobinai K. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Review
Makita, Shinichi
Imaizumi, Katsuaki
Kurosawa, Saiko
Tobinai, Kensei
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
title Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
title_full Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
title_fullStr Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
title_full_unstemmed Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
title_short Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
title_sort chimeric antigen receptor t-cell therapy for b-cell non-hodgkin lymphoma: opportunities and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385623/
https://www.ncbi.nlm.nih.gov/pubmed/30815024
http://dx.doi.org/10.7573/dic.212567
work_keys_str_mv AT makitashinichi chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges
AT imaizumikatsuaki chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges
AT kurosawasaiko chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges
AT tobinaikensei chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges